tbuckley/cabot-search huggingface dataset:
Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETs): Consensus guidelines from the Commonwealth NET collaboration (CommNETs) in conjunction with the North American NET Society (NANETS)
Authors: S. Singh, L. Moody, D. Chan, D. Metz, J. Strosberg, E. Segelov
Journal: Annals of Oncology (2017)
Relationship between PD-L1 expression and survival in head and neck squamous cell carcinoma (HNSCC) patients (pts)
Authors: M. Stokes, R. Wang, S. Wildsmith, M. Secrier, H.K. Angell, C. Barker, J. Walker, P. Scorer, M.C. Rebelatto, N. Shire
Journal: Annals of Oncology (2017)
Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-Positive metastatic breast cancer (MBC) after prior HP- or TDM/P-based therapy.
Authors: Neil M. Iyengar, Lillian Mary Smyth, Maxine S. Jochelson, Diana Lake, Ayca Gucalp, Maura N. Dickler, Shari Beth Goldfarb, Asma Latif, Shanu Modi, Jasmeet Chadha Singh, Tiffany A. Traina, Tiffany A. Troso-Sandoval, Gary Ulaner, Daniel F. Argolo, Kellie Jack, Daniel Lichtenauer, Jose Baselga, Larry Norton, Clifford A. Hudis, Chau T. Dang
Journal: Journal of Clinical Oncology (2016)

611 Background: The combination of taxanes with HP for first line treatment of HER2-positive MBC is associated with improved progression-free (PFS) and overall survival (OS). Previous data demonstrated that treatment per physician’s choice beyond second line leads to median PFS of 3 months. However, the efficacy of continuing HP-based treatment after progression on P-based therapy is unknown. Methods: This is a single arm phase II trial of G with HP. Eligible patients (pts) had HER2-positive (IHC 3+ or FISH > 2.0) MBC with prior HP-based treatment and ≤ 3 prior chemotherapies. Pts received G (1200 mg/m2) on days 1 and 8 of a q 3 week (w) cycle, and H (8 mg/kg load → 6 mg/kg) and P (840 mg load → 420 mg) q3w. The primary endpoint is PFS at 3 months. Secondary endpoints include OS, safety and tolerability. An exploratory endpoint is to compare PFS by RECIST criteria versus 18-F FDG-PET response criteria. Using a Simon optimal 2-stage design, 21 pts will be enrolled in stage 1. If 12/21 (57%) pts are progression free at 3 months, stage 2 will accrue for a total of 45 pts. Results: As of 1-30-16, 17 pts are enrolled; 12 are evaluable at 3 months and 5 have not had 3-month evaluation. At 3 months, 7/12 (58%) are progression free (1 CR, 1 PR, 5 SD); 5 pts progressed. The 3 month-PFS results for all pts will be updated. There are no cardiac or febrile neutropenic events to date. 4 pts required G dose reduction (3 due to grade 3 neutropenia and 1 due to grade 3 vomiting) and the study will be amended to lower initial G dose to 1000 mg/m2. Conclusions: The preliminary 3 month-PFS is 58% in evaluable pts. Updated data for 21 pts in stage 1 will be presented. Clinical trial information: NCT02252887.
Desenvolvimento de uma rede electrónica europeia para as doenças transmissíveis: o programa IDA-HSSCD
Authors: J Weinberg, H Nohynek, J Giesecke
Journal: Eurosurveillance (1997)

O desenvolvimento da Uniao Europeia (UE), um bloco multinacional onde as pessoas e as mercadorias circulam livremente, acentua as dificuldades no dominio da vigilância das doencas transmissiveis ligadas as trocas comerciais e as viagens internacionais. Em resultado, desenvolveram-se, no âmbito da vigilância as colaboracoes internacionais entre os varios paises da UE. Estas colaboracoes tem tido sucesso na identificacao de surtos que afectaram mais do que um pais (1-4).
A randomized, open-label comparison of lorlatinib versus crizotinib as first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer
Authors: A.T. Shaw, T.M. Bauer, T. Takahashi, C.S. Baik, A. Polli, M. Carpentieri, J-F. Martini, B.J. Solomon
Journal: Annals of Oncology (2017)
Infecções por SARM adquiridas na comunidade em crianças na Grécia
Authors: S Vourli, D Perimeni, A Makri, M Polemis, A Voyiatzi, A Vatopoulos
Journal: Eurosurveillance (2005)

O estudo seguinte apresenta as caracteristicas de 20 estirpes de Staphylococcus aureus resistente a meticilina (SARM) adquirido em comunidade, isoladas num hospital pediatrico de Atenas. Dezoito estirpes, provenientes de infeccoes dermatologicas e de tecidos moles tinham genes para a leucocidina de Panton-Valentine (PVL). Estas 18 estirpes apresentam uma resistencia ao acido fusidico , a tetraciclina e a kanamicina e o seu perfil de electroforese em campo pulsado e igual aquele do clone de CA-SARM ST80 circulando em varios paises da Europa que ja foi bem descrito.
Results of a randomized, double-blind placebo-controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features.
Authors: Jacqueline Claudia Barrientos, Jennifer R. Brown, Ehab L. Atallah, Steven Coutre, Javier De La Serna, Herbert Aaron Eradat, Charles Michael Farber, Ann Janssens, Javier Loscertales, Christopher Pocock, Mazyar Shadman, Adeboye H. Adewoye, Maria Aiello, Lyndah Dreiling, Yeonhee Kim, Andrew David Zelenetz, Stephan Stilgenbauer
Journal: Journal of Clinical Oncology (2016)

7514 Background: Patients (pts) with relapsed CLL and adverse prognostic features respond poorly to standard treatment. Here we present a subgroup analysis from a phase 3 randomized double-blind placebo-controlled study. We evaluated progression-free survival (PFS) in this pt population enrolled between June 2012 and August 2014. Methods: All 416 pts (207/209 on the idelalisib (IDELA)/placebo [plb] arms, respectively) had BR for 6 cycles Q 28 days (B = 70 mg/m2 D1, D2 of each cycle; R = 375 mg/m2 C1 and 500 mg/m2 C2-6) and IDELA 150 mg BID or plb. IDELA/plb continued until independent review committee confirmation of disease progression, death, intolerable toxicity, or withdrawal of consent. Mutational analysis was centrally performed. Median time on study was 12 months. Results: Improvement in PFS was observed on the IDELA vs plb arm in all adverse-risk categories evaluated (Table). Conclusions: IDELA with BR consistently increased PFS in all risk categories evaluated. The safety profile was consistent with prior reported studies. This evidence supports the combination of IDELA with BR as an important treatment option for pts with relapsed CLL and adverse prognostic features. Clinical trial information: NCT01569295.Adverse Prognostic Feature (N, IDELA/placebo arms) Med PFS (months) IDELA + BR Plb+ BR HR (point estimate), p value All pts (207/209) 23.1 11.1 0.33, P<0.001 Del11q: . . . Yes (78/77) 23.1 8.9 0.24, P<0.001 No (125/129) 23.1 11.1 0.41, P<0.001 Tumor: . . . ≤ 5 cm (67/73) NR 11.1 0.35, P<0.001 > 5 cm (140/136) 23.1 10.4 0.35, P<0.001 Del 17p or p53: . . . Either (69/68) 11.1 8.3 0.50, P=0.002 Neither (138/141) 24.6 11.1 0.22, P<0.001 IGHV: . . . mut (34/36) NR 11.2 0.22, P<0.001 unmut (173/173) 21.8 11.0 0.38, P<0.001
GW28-e0642 Interleukin 37 suppresses inflammatory responses in human aortic valve interstitial cells through inhibition of Notch1-NF-kappaB axis
Authors: Qingchun Zeng, Tianyu Xu, Jiaying Li, Xi Yang, Qiong Zhan, Yufeng Zhai, Lihua Ao, Xianzhong Meng, Dingli Xu
Journal: Journal of the American College of Cardiology (2017)
GW28-e0806 Pyr1-Apelin 13 is a negative modulator of angiotensin II-mediated adverse myocardial hypertrophy, remodeling and fibrosis
Authors: Jiuchang Zhong, ZhenZhou Zhang, HaiYan Jin, Wang Wang, YuWen Cheng, Xueyi Chen, YingLe Xu, Bei Song, Josef M. Penninger, Gavin Y. Oudit
Journal: Journal of the American College of Cardiology (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Authors: Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mikhael, Ravi Vij, Brigitte Pegourie, Lofti Benboubker, Thierry Facon, Martine Amiot, Philippe Moreau, Elizabeth A. Punnoose, Stefanie Alzate, Martin Dunbar, Tu Xu, Suresh K. Agarwal, Sari Heitner Enschede, Joel D. Leverson, Jeremy A. Ross, Paulo C. Maciag, Maria Verdugo, Cyrille Touzeau
Journal: Blood (2017)
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastoma
Authors: M.J. van den Bent, L.A. Roberts-Rapp, P. Ansell, J. Lee, J. Looman, E. Bain, C. Ocampo, K.D. Holen, E.J. Gomez, A.B. Lassman
Journal: Annals of Oncology (2017)
La rage, une maladie négligée
Authors: A. R. Fooks
Journal: Eurosurveillance (2005)

L’Europe doit continuellement faire face a la menace que representent les maladies zoonotiques incluant des bacteries anciennes telles que Mycobacterium tuberculosis, des virus DNA comme le SRAS-CoV et les virus RNA comprenant les virus Heninipah, les virus de la grippe aviaire et les lyssavirus emergents.
A pooled analysis evaluating the combination antiemetic therapy on chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk
Authors: M. Shimokawa, T. Kogawa, J. Nishimura, T. Satoh, K. Nakata, T. Hayashi, R. Matsui, K. Aiba, K. Tamura
Journal: Annals of Oncology (2017)
Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis
Authors: Philipp Schuetz, Yannick Wirz, Ramon Sager, Mirjam Christ-Crain, Daiana Stolz, Michael Tamm, Lila Bouadma, Charles E Luyt, Michel Wolff, Jean Chastre, Florence Tubach, Kristina B Kristoffersen, Olaf Burkhardt, Tobias Welte, Stefan Schroeder, Vandack Nobre, Long Wei, Heiner C Bucher, Djillali Annane, Konrad Reinhart, Ann R Falsey, Angela Branche, Pierre Damas, Maarten Nijsten, Dylan W de Lange, Rodrigo O Deliberato, Carolina F Oliveira, Vera Maravić-Stojković, Alessia Verduri, Bianca Beghé, Bin Cao, Yahya Shehabi, Jens-Ulrik S Jensen, Caspar Corti, Jos A H van Oers, Albertus Beishuizen, Armand R J Girbes, Evelien de Jong, Matthias Briel, Beat Mueller
Journal: The Lancet Infectious Diseases (2017)
Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
Authors: Katja C. Weisel, Jesus San Miguel, Gordon Cook, Merav Leiba, Kenshi Suzuki, Shaji Kumar, Michele Cavo, Herve Avet-Loiseau, Hang Quach, Vania Hungria, Suzanne Lentzsch, Roman Hajek, Pieter Sonneveld, Kaida Wu, Xiang Qin, Christopher Chiu, David Soong, Ming Qi, Jordan Mark Schecter, Meletios A. Dimopoulos
Journal: Journal of Clinical Oncology (2017)

8006 Background: In 2 randomized phase 3 trials of RRMM patients (pts), DRd (POLLUX) or DVd (CASTOR) significantly improved PFS and deepened responses compared with Rd or Vd alone, respectively. The novel mechanism of action of daratumumab (D) may improve the poor prognosis associated with high-risk cytogenetic abnormalities in RRMM. Therefore, we examined the efficacy of DRd and DVd among RRMM pts with standard (std) or high cytogenetic risk status. Methods: Bone marrow aspirates were collected at screening and assessed centrally via next generation sequencing (NGS). Pts with high-risk cytogenetics included those who had ≥1 of the following abnormalities: t(4;14), t(14;16), or del17p; std-risk pts were defined as those confirmed negative for these abnormalities. Efficacy analyses included PFS and ORR. Results: Samples from 311/569 pts in POLLUX and 353/498 pts in CASTOR were assessed via NGS. In POLLUX, the median duration of follow-up was 17.3 months. Significantly longer median PFS and numerically higher ORR were observed with DRd vs Rd among high-risk patients, and significant improvements in these outcomes were observed in std-risk patients (Table). In CASTOR, the median duration of follow-up was 13.0 months. Significantly longer median PFS and higher ORR were observed with DVd vs Vd among both high- and std-risk pts (Table). Concordance rates for t(4;14), t(14;16), and del17p were high (88%-98%) between NGS and FISH. Updated data, including subgroup analyses, will be presented. Conclusions: In RRMM pts, the addition of D to standard-of-care regimens improved outcomes regardless of cytogenetic risk status. Targeting CD38 by combining D with Rd or Vd appears to improve the poor outcomes associated with high-risk cytogenetic status. See table. Clinical trial information: NCT02136134 and NCT02076009. [Table: see text]
The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM)
Authors: D. Sener Dede, H. Tatli Dogan, F.B. Asan, B. Gumuskaya Ocal, S. Ayik, M.A.N. Sendur, A. Ulas, B. Bilgin, M. Hizal, M.B. Akinci, K. Silay, B. Yalçın
Journal: Annals of Oncology (2017)
Sedentary Behavior and Subclinical Cardiac Injury
Authors: Josephine L. Harrington, Colby Ayers, Jarett D. Berry, Torbjørn Omland, Ambarish Pandey, Stephen L. Seliger, Christie M. Ballantyne, Jacquelyn Kulinski, Christopher R. deFilippi, James A. de Lemos
Journal: Circulation (2017)
Alleviating the access abyss in palliative care and pain relief—an imperative of universal health coverage: the Lancet Commission report
Authors: Felicia Marie Knaul, Paul E Farmer, Eric L Krakauer, Liliana De Lima, Afsan Bhadelia, Xiaoxiao Jiang Kwete, Héctor Arreola-Ornelas, Octavio Gómez-Dantés, Natalia M Rodriguez, George A O Alleyne, Stephen R Connor, David J Hunter, Diederik Lohman, Lukas Radbruch, María del Rocío Sáenz Madrigal, Rifat Atun, Kathleen M Foley, Julio Frenk, Dean T Jamison, M R Rajagopal, Felicia Marie Knaul, Paul E Farmer, Huda Abu-Saad Huijer, George A O Alleyne, Rifat Atun, Agnes Binagwaho, Snežana M Bošnjak, David Clark, James F Cleary, José R Cossío Díaz, Liliana De Lima, Kathleen M Foley, Julio Frenk, Cynthia Goh, Pascal J Goldschmidt-Clermont, Mary Gospodarowicz, Liz Gwyther, Irene J Higginson, Thomas Hughes-Hallett, David J Hunter, Dean T Jamison, Eric L Krakauer, Diederik Lohman, Emmanuel B K Luyirika, Maria E Medina Mora, Faith N Mwangi-Powell, Sania Nishtar, Megan E O'Brien, Lukas Radbruch, M R Rajagopal, K Srinath Reddy, María del Rocío Sáenz Madrigal, Judith A Salerno, Afsan Bhadelia, Silvia Allende, Héctor Arreola-Ornelas, Nahid Bhadelia, Mariana Calderon, Stephen R Connor, Victoria Y Fan, Octavio Gómez-Dantés, Jorge Jiménez, Christian R Ntizimira, Pedro E Perez-Cruz, Isaias Gerardo Salas-Herrera, Dingle Spence, Mark R Steedman, Stéphane Verguet, Julia D Downing, Bishnu D Paudel, Maia Elsner, James Andrew Gillespie, Karen J Hofman, Xiaoxiao Jiang Kwete, Quach Thanh Khanh, Karl A Lorenz, Oscar Méndez Carniado, Rachel Nugent, Natalia M Rodriguez, Emily B Wroe, Camilla Zimmerman
Journal: The Lancet (2017)
Ipilimumab in the treatment of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience.
Authors: Shaheer A. Khan, Margaret Callahan, Michael Andrew Postow, Paul B. Chapman, Gary K. Schwartz, Mark Andrew Dickson, Sandra P. D'Angelo, Jason John Luke, Mark J. Bluth, Ruth Ann Roman, Mary Montefusco, Christopher Andrew Barker, David H. Abramson, Jedd D. Wolchok, Richard D. Carvajal
Journal: Journal of Clinical Oncology (2012)

8549 Background: Ipilimumab (ipi) is an antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4) and improves overall survival in patients (pts) with metastatic melanoma. Uveal melanoma (UM) is a rare and biologically unique disease subtype with no known effective systemic therapy. Ipi has proven efficacy in cutaneous melanoma (CM), but limited data exists regarding its activity in UM. We reviewed our single-institutional experience with ipi in advanced UM. Methods: After IRB approval, the MSKCC melanoma database was queried for patients with metastatic UM treated with ipi between 03/08-01/12. Radiographic response by RECIST and immune-related response criteria (irRC) was assessed by a single radiologist blinded to clinical outcomes. Immune-related adverse events (irAEs), survival and absolute lymphocyte count (ALC) were also evaluated. Results: 20 pts were identified: the median age was 61yrs (range 46-83), 55% were male, 85% had liver metastases, 60% had elevated LDH, and pts reported a median of 1 prior therapies (range 0-5). Pts received a median of 4 doses (range 1-16) of ipi. Response rates (RR) by irRC at 12 and 24 wks are listed below. Among pts with stable disease (SD) at 12 wks, the median time to progression was 30.6 wks (range 19.6-83), with one partial response (PR) occurring after 24 wks (overall RR 10%). Responses were observed in lung, liver and peritoneal metastases. Pts with an ALC ≥ 1.0 at 7 wks had a trend toward a higher clinical benefit (CB= CR + PR + SD) than pts with ALC &lt; 1.0 (5/12 [42%] vs 0/5 [0%]; p= .09), consistent with prior studies in CM. To date, median survival for the group is 8.6 mos (95% CI, 3.5-NR), with two ongoing PRs (3+ yrs and 24+ wks). Reported irAEs include rash/pruritis (10/20), hepatitis (1/20), colitis (1/20), pancreatitis (1/20) and uveitis (1/20). Conclusions: Ipi has potential for benefit in pts with advanced UM; RR and irAE rates are similar to those observed in pts with advanced CM. Further evaluation of ipi in the treatment of UM, including identification of potential biomarkers of CB, is warranted. [Table: see text]
Whole-Genome Sequencing of African Dogs Provides Insights into Adaptations against Tropical Parasites
Authors: Yan-Hu Liu, Lu Wang, Tao Xu, Xiaomin Guo, Yang Li, Ting-Ting Yin, He-Chuan Yang, Yang Hu, Adeniyi C Adeola, Oscar J Sanke, Newton O Otecko, Meng Wang, Yaping Ma, Olaogun S Charles, Mikkel-Holger S Sinding, Shyam Gopalakrishnan, José Alfredo Samaniego, Anders J Hansen, Carlos Fernandes, Philippe Gaubert, Jane Budd, Philip M Dawuda, Eli Knispel Rueness, Lubin Jiang, Weiwei Zhai, M Thomas P Gilbert, Min-Sheng Peng, Xiaopeng Qi, Guo-Dong Wang, Ya-Ping Zhang
Journal: Molecular Biology and Evolution (2017)

Natural selection in domestic dogs is of great interest in evolutionary biology since dogs have migrated to every inhabited continent of the world alongside humans, and adapted to diverse environments. Here, we explored their demographic history and genetic basis of adaptation to the tropical African environment using whole genome analyses of 19 African indigenous dogs from Nigeria. Demographic analysis suggests that the ancestors of these dogs migrated into Africa from Eurasia 14,000 years ago and underwent a severe founder effect before population expansion. Admixture analysis further reveals that African dog genomes contain about 1.88-3.50% introgression from African golden wolves (Canis anthus). Population genetic analysis identifies 50 positively selected genes linked with immunity, angiogenesis, ultraviolet protection, as well as insulin secretion and sensitivity that may contribute to adaptation to tropical conditions. One of the positively selected genes, adhesion G protein-coupled receptor E1 (ADGRE1), has also been found to be association with severe malaria resistance in African human populations. Functional assessments showed that ADGRE1 provides protective host defense against Plasmodium infections. This result, together with the fact that the inflammatory response to canine babesiosis is similar to complicated falciparum malaria in humans, support the dogs as a model for the study of malaria control and treatment.
B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin for Risk Stratification in Low-Flow, Low-Gradient Aortic Stenosis
Authors: Abdellaziz Dahou, Marie-Annick Clavel, Romain Capoulade, Kim O’Connor, Henrique B. Ribeiro, Nancy Côté, Florent Le Ven, Josep Rodés-Cabau, Jean G. Dumesnil, Patrick Mathieu, Philippe Pibarot
Journal: JACC. Cardiovascular imaging (2017)
Indagine su focolaio epidemico di amebiasi in Georgia
Authors: P Kreidl, P Imnadze, L Baidoshvili, D Greco
Journal: Eurosurveillance (1999)

Entamoeba histolytica, un protozoo parassita, e diffuso in tutto il mondo e si stima che il 12% della popolazione mondiale ne sia infettata (1). La prevalenza dell'infezione e variabile: 1% nei paesi industrializzati, tra il 50 e l'80% nei paesi tropicali, dove e comune la trasmissione delle cisti di E. histolytica per mezzo di acqua non depurata. Le modalita d'infezione piu comuni comprendono l'ingestione di cibo e bevande contaminati con cisti di E. histolytica provenienti da feci umane e i contatti oro-fecali diretti (2,3), ma i focolai di E. histolytica vengono raramente notificati. I portatori di cisti costituiscono il principale serbatoio infettivo.
Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.
Authors: Douglas Edward Gladstone, Marc Andre, Jan M. Zaucha, Sarit E. Assouline, Naresh Bellam, Nicola Cascavilla, Eric Jourdan, Amit W. Panwalkar, Caterina Patti, Clemens Schulte, Francesco Zaja, Trishna Goswami, Nairouz Elgeioushi, David Spaner
Journal: Journal of Clinical Oncology (2014)

3028 Background: Patients (pts) with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL) need therapies that induce prolonged disease control. MEDI-551, an affinity-optimized anti-CD19 antibody, destroys CLL cells by antibody-dependent cellular cytotoxicity. A phase 2 randomized, open-label study (NCT01466153) is evaluating the clinical activity and safety/tolerability of 2 doses of MEDI-551 + bendamustine compared to rituximab + bendamustine in RR CLL patients. Methods: Pts were initially randomized to receive bendamustine + MEDI-551 2 or 4 mg/kg or rituximab (R). Safety assessments include adverse events (AEs) and laboratory parameters. Disease response was determined using 2008 International Working Group criteria. Results: The safety population comprised 124 pts across all arms. Median age was 66y (range 41–81); with deletion (del) (17p): 9%, del (11q): 22%, del (13q): 31%, trisomy 12: 11%. Median number of treatment cycles: 4 (range 1–6). The most common (≥20%) treatment-related AEs with MEDI-551 were infusion-related reaction (IRR), fatigue and nausea; neutropenia and nausea were most common with R; most treatment-related AEs were grade 1/2; grade 3/4 treatment-related AEs are listed in Table 1. 20% of pts receiving MEDI-551and 18% patients receiving R discontinued treatment due to AEs. An interim analysis of the MEDI-551-treated pts (25 per arm) showed response rates of 48 vs. 64% in the 2 vs. 4 mg/kg arms. Conclusions: MEDI-551 in combination with bendamustine has a manageable toxicity profile that appears to be different compared to rituximab in RR CLL patients. MEDI-551 dosed at 4 mg/kg as compared to 2 mg/kg may have a greater efficacy without any increase in toxicity. Clinical trial information: NCT01466153. Treatment-related grade 3/4 AEs (≥5% of patients). MEDI-551 Rituximab n (%) 2 mg/kg (n=33) 4 mg/kg (n=44) (n=47) Pts reporting ≥1 event 18 (55) 16 (36) 21 (45) Neutropenia 6 (18) 4 (9) 11 (23) Febrile neutropenia 0 1 (2) 5 (11) Thrombocytopenia 0 1 (2) 5 (11) IRR 6 (18) 4 (9) 1 (2) Decreased neutrophils 1 (3) 2 (5) 3 (6) Cytokine release syndrome 2 (6) 0 0 Tumor lysis syndrome 0 2 (5) 0
Phase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with first-line or recurrent/refractory glioblastoma
Authors: P.Y. Wen, K. Shih, D. Schiff, R. Brachmann, R. Weitzman, T. Cloughesy
Journal: Annals of Oncology (2017)
Results of the LMS03 phase II study evaluating gemcitabine combined with pazopanib as a 2nd-line treatment for metastatic/relapsed leiomyosarcomas (uterine or soft tissue) after failure of anthracycline-based chemotherapy: The UNICANCER SARCOME 11 study
Authors: P. Pautier, N. Penel, I. Ray-Coquard, A. Italiano, E. Bompas, C. Delcambre, J-O. Bay, F. Bertucci, J. Delaye, C. Chevreau, D. Cupissol, L. Bozec Le Moal, J-C. Eymard, A. Thyss, N. Isambert, C. Guillemet, M. Rios, S. Piperno-Neumann, G. Chenuc, F. Duffaud
Journal: Annals of Oncology (2017)